זפוסיה 0.46 מ"ג - Zeposia 0.46 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L04AE Sphingosine-1-phosphate (S1P) receptor modulators | |||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | פ××× - PER OS | |||||||||||||
| צ×רת ××× ×× | קפס×××ת, CAPSULES ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | Zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.ZEPOSIA is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults. | |||||||||||||
| ||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | |||||||||||||
| ×ת××××ת × ×× | Contraindications | |||||||||||||
| ת×פע×ת ××××× | Undesirable effects | |||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | |||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | |||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | |||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | |||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
Â
 | |||||||||||||
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×פ×ס×× 0.46 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | CELGENE CORPORATION, USA |
| ×©× ××¢× ×ר×ש×× | BRISTOL - MYERS SQUIBB, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 7/2020. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 16/10/2024 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־16 באוקטובר 2024 ב־19:47